AMDD Implementation in Myanmar

1. Key takeaways

The implementation of the ASEAN Medical Device Directive (AMDD) in Myanmar follows a dual track of international commitment plus administrative conversion: Myanmar deposited its instrument of ratification with the ASEAN Secretariat in July 2018, committing to advance domestic conversion within a 5-year harmonisation period counted from 2016; at the legislative level, the draft dedicated law has been submitted to the Attorney General’s Office; at the execution level, the Myanmar FDA applies the AMDD technical standards directly through administrative guidance and technical guidelines.

• The AMDD was adopted in 2015 and functions in Myanmar as the technical benchmark for review, not as a directly applicable statute.
• The 5-year harmonisation timeline from 2016 was reported by the Myanmar Food and Drug Administration at the 7th AMDC meeting.
• The draft dedicated law is pending with the Attorney General’s Office and, once approved, must be further submitted to the Myanmar Parliament for comments.
• The residual enforcement authority remains section 3(3)(d) of the Public Health Law 1972.
• This pattern of commitment first, legislation later is the key to understanding Myanmar device regulation: prepare technical documentation to AMDD requirements and formats and procedures to FDA administrative guidance at the same time.
• In practice, the two tracks interact: the technical content of a submission is judged against AMDD logic, while any deviation in format or procedure is judged against the FDA guideline, so deficiencies can arise on either track independently of the other.
• For regional planners, the practical meaning is that Myanmar accepts products whose documentation was already structured for other AMDD-based markets, but the packaging of that documentation must still be rebuilt to the FDA e-Submission format.

2. Legal basis

The instruments below trace how an international commitment becomes an operating review standard in Myanmar. Each row is a different layer of the same implementation chain, and no single row alone captures the applicable rules.

3. Expert insights

Insight 1: the AMDD in Myanmar is a technical standard, not a directly applicable law. Myanmar converts the technical requirements of the AMDD into operational review standards through FDA administrative guidance. When citing the framework, companies should express it as the Myanmar FDA applying AMDD standards in review, rather than referring to a specific AMDD article as the legal basis.

Insight 2: the 5-year harmonisation period runs from 2016, and the dedicated law has still not landed. This time gap tells companies that Myanmar’s legislative progress cannot be predicted on a conventional timetable. Medium and long-term planning must be prepared for both scenarios simultaneously: a dedicated law may be enacted at any time, or it may remain unenacted for a long period.

Insight 3: administrative guidance carries real binding force. Although administrative guidance ranks below statute, it is the direct basis for registration review. A company that fails to follow the format requirements will trigger a deficiency request directly, and the resulting exchanges extend the review timeline.

Insight 4: the technical guideline prescribes all key document formats. Sections 5, 6, 7 and 8 of the guideline respectively provide the formats of the authorised letter, the product safety declaration, the declaration of conformity and the mandatory problem reporting form. Using the prescribed formats is the most effective means of avoiding rejection at formal screening, because formal screening is the first gate of the e-Submission process and any non-conforming text is returned before technical review begins.

Insight 5: compared with ASEAN markets that have completed legislative conversion, Myanmar is in a transitional state. Companies’ compliance strategies should retain sufficient flexibility so that they can adapt quickly once a dedicated law is enacted. Whether and when that adaptation will be required remains a practical estimate pending verification against future official announcements. Companies should therefore maintain a version of the dossier that can be upgraded from AMDD structure to a national dossier structure without rebuilding the underlying evidence.

4. Practical recommendations

• Prepare the technical documentation to AMDD technical standards. Organise the classification logic, risk management and clinical evaluation under the AMDD system.
• Prepare formats and procedures to FDA administrative guidance and the technical guideline. Use the format texts prescribed in the guideline and follow the submission process strictly.
• Retain complete records of FDA announcements and correspondence. These serve as the evidence chain for changes in interpretation over time.
• Pre-arrange legislative change clauses in contracts. Agree in advance on the cooperation obligations of each party once a dedicated law is enacted.
• Plan the registration rhythm for a transitional state. Avoid betting long-cycle investments on the assumption that the current interpretation will not change.

5. Verification checklist

• □ Confirmed that Myanmar deposited its AMDD instrument of ratification in July 2018
• □ Confirmed that the harmonisation timeline is 5 years, counted from 2016
• □ Confirmed that the Myanmar FDA applies AMDD standards in review
• □ Confirmed that the draft dedicated law is pending with the Attorney General’s Office
• □ Organised the technical documentation under the AMDD system
• □ Used the format texts prescribed in the technical guideline
• □ Established a register of FDA announcements and correspondence

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com